Literature DB >> 11371558

NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer.

P A Hubbard1, A L Shen, R Paschke, C B Kasper, J J Kim.   

Abstract

NADPH-cytochrome P450 oxidoreductase catalyzes transfer of electrons from NADPH, via two flavin cofactors, to various cytochrome P450s. The crystal structure of the rat reductase complexed with NADP(+) has revealed that nicotinamide access to FAD is blocked by an aromatic residue (Trp-677), which stacks against the re-face of the isoalloxazine ring of the flavin. To investigate the nature of interactions between the nicotinamide, FAD, and Trp-677 during the catalytic cycle, three mutant proteins were studied by crystallography. The first mutant, W677X, has the last two C-terminal residues, Trp-677 and Ser-678, removed; the second mutant, W677G, retains the C-terminal serine residue. The third mutant has the following three catalytic residues substituted: S457A, C630A, and D675N. In the W677X and W677G structures, the nicotinamide moiety of NADP(+) lies against the FAD isoalloxazine ring with a tilt of approximately 30 degrees between the planes of the two rings. These results, together with the S457A/C630A/D675N structure, allow us to propose a mechanism for hydride transfer regulated by changes in hydrogen bonding and pi-pi interactions between the isoalloxazine ring and either the nicotinamide ring or Trp-677 indole ring. Superimposition of the mutant and wild-type structures shows significant mobility between the two flavin domains of the enzyme. This, together with the high degree of disorder observed in the FMN domain of all three mutant structures, suggests that conformational changes occur during catalysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371558     DOI: 10.1074/jbc.M101731200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

Review 1.  The syndrome of 17,20 lyase deficiency.

Authors:  Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

2.  Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.

Authors:  Yi Jin; Mo Chen; Trevor M Penning; Walter L Miller
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

Review 3.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 4.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

5.  Monitoring shifts in the conformation equilibrium of the membrane protein cytochrome P450 reductase (POR) in nanodiscs.

Authors:  Maria Wadsäter; Tomas Laursen; Aparajita Singha; Nikos S Hatzakis; Dimitrios Stamou; Robert Barker; Kell Mortensen; Robert Feidenhans'l; Birger Lindberg Møller; Marité Cárdenas
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

6.  Restricting the conformational freedom of the neuronal nitric-oxide synthase flavoprotein domain reveals impact on electron transfer and catalysis.

Authors:  Yue Dai; Mohammad Mahfuzul Haque; Dennis J Stuehr
Journal:  J Biol Chem       Date:  2017-02-23       Impact factor: 5.157

7.  Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450.

Authors:  Djemel Hamdane; Chuanwu Xia; Sang-Choul Im; Haoming Zhang; Jung-Ja P Kim; Lucy Waskell
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

8.  Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.

Authors:  Pauline Lancia; Tiphaine Adam de Beaumais; Valéry Elie; Florentine Garaix; Marc Fila; François Nobili; Bruno Ranchin; Pascale Testevuide; Tim Ulinski; Wei Zhao; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Pediatr Nephrol       Date:  2018-02-04       Impact factor: 3.714

9.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

10.  Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering.

Authors:  Jacqueline Ellis; Aldo Gutierrez; Igor L Barsukov; Wei-Cheng Huang; J Günter Grossmann; Gordon C K Roberts
Journal:  J Biol Chem       Date:  2009-10-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.